Thomas J. Schall - 15 Jan 2026 Form 4 Insider Report for Immuneering Corp (IMRX)

Reporting relationship: Director
Issuer ticker: IMRX
Reported as of: 15 Jan 2026
Net transaction value: +$101,041
SEC form: 4
Accepted by SEC: 20 Jan 2026, 09:17:29 UTC
Prior SEC filing: 30 Jun 2025
Next SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael D. Bookman, Attorney-in-Fact for Thomas J. Schall

Key filing fact

Thomas J. Schall filed Form 4 for Immuneering Corp (IMRX) on 20 Jan 2026.

Key facts

This page summarizes Thomas J. Schall's Form 4 filing for Immuneering Corp (IMRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Jan 2026, 09:17.

Change

Previous filing in this sequence was filed on 30 Jun 2025.
Current net transaction value: +$101,041.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001423084 Primary reporting owner

Schall Thomas J.

Relationship: Director
Address: C/O IMMUNEERING CORPORATION, 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE
Signature: /s/ Michael D. Bookman, Attorney-in-Fact for Thomas J. Schall
Signature date: 20 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMRX transaction

Class A Common Stock

Purchase

Transaction value: $101,041
Shares: +21,645
Change %: +41%
Price: $4.67
Shares after: 74,530
Date: 15 Jan 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.61 to $4.69. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.